Albert Science International Organization

ARTICLE DESCRIPTION: 

T. Maity, B. Chandra. Development of Preformulation Parametes of Celecoxib: Solubility, Partition Coeficient, Crystalline Characteristics, Flow Properties, FTIR and DSC Analysis, ASIO Journal of Pharmaceutical & Herbal Medicines Research, 2015,1(1): 48-54.

ARTICLE TYPE: RESEARCH

dids/doi No.: 12.2015-59256428

dids link: http://dids.info/didslink/12.2015-59256428/

ABSTRACT:

Celecoxib is a nonsteroidal anti-inflammatory drug that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of Celecoxib is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of cyclooxygenase-2 (COX-2), and at therapeutic concentrations in humans, Celecoxib does not inhibit the cyclooxygenase-1 (COX-1) isoenzyme. The physicochemical parameters like solubility, partition coeficient, crystalline characteristics, flow properties, FTIR and DSC analysis were carried out. The aim of this research work was to develop the spectrophotometric methods for evaluation the celecoxib and to analyse the various physicochemical parameters of this drug. It is the part of investigation earlier to the design, development of pharmaceutical dosage forms. Drug was assayed for purity test and it was found 98.87±0.61 %. In presence of various solvents systems the regression co-efficient obtained from the standard plots were nearing about 1.0 and which proved the linearity of the analytical methods. All the models followed Beer-Lambert’s law and therefore can be analyzed by UV spectrophotometer.  The FT-IR spectra of pure celecoxib shown characteristic bands at 1229 & 1274 cm^-1(-CF₃), 1446 cm^-1 (-N-N-), 3417 cm^-1 (-SO₂NH₂). Celecoxib showed a single sharp endothermic peak corresponding to the melting of the drug at 165.21^oC (T_onset=161.15^oC, T_end=167.73^oC, area=1066.29 mJ, ΔH_f=0.1066 KJ/mol and ΔH=106.63 J/g).

Key words: Celecoxib, Solubility, FTIR, DSC, partition coeficient.

1. Indian Pharmacopoeia, Indian Pharmacopoeial commission, Ministry of Health and Family Welfare, New Delhi, India, 2007, (1), 241-244.
2. United States Pharmacopoiea-28, NF-23, Asian Edition, United States Pharmacopoeial Convention, INC. Twin brook Parkway, Rockville, MD, U.S.A., 2005, p 184.
3. Park S, Choi H.  The effects of surfactants on dissolution profiles of poorly water soluble acidic drugs, Int. J. Pharm., 2006, 321, 35-41.
4. Aulton M E. Pharmaceutics: the science of dosage form design, In: Wells J, Pharmaceutical preformulation: the physicochemical properties of drug substances, 2nd ed., Edinburgh, Churchill Livingstone, 2005,121.
5. Andrews SA, Christy KW, Roger LD, Celecoxib: A COX- 2 Inhibitor, The American J. Managed Care. 1999, 5(4), 511-524.
6. Baboota S, Faiyaz S, Ahuja A, Ali J, Shafiq S, Ahmad S. Development and validation of a stability-indicating HPLC method for analysis of celecoxib (CXB) in bulk drug and microemulsion formulations. Acta Chromatographica, 2007, 18, 116-129.
7. Chan CML, Ma BBY, Wong SC, Chan ATC. Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression. Biomed. Pharmacother., 2005, 59, S268-S271. 
8. Kopeck J, Kopeckova P, Brondsted H, Rath R, Lkesue K. Polymers for colon-specific drug delivery, Journal of controlled release, 1992, 19, 121-130.
9. Andrews SA, Christy KW, Roger LD. Celecoxib: A COX- 2 Inhibitor. The American J. Managed Care., 1999, 5(4), 511-524.
10. Azzaniga A, Iamartino P, Maffino G, Sangalli ME. Oral delayed release system for colonic specific drug delivery. International Journal of Pharmaceutics, 1994, 108, 77-83.